DECEMBER MARKETS CHRISTMAS GIFT

(Click on image to enlarge)

Finding the stock markets accommodating may feel comforting for some but for this investor, I am after the doubles and triples, and of course, the few homerun stocks pick to end the year of 2019 moving into 2020.  

How does one keep ahead of all the quant geniuses when finding the perfect Biopharmacitcul companies with the possibility of gaining Orphan Drug status?  We have a few to review and bring onto your radar. 

The first Biopharm stock is Dermira, Inc. DERM that has seen recently, it's a share price rise significantly in the last several weeks of trading. Why? Simple, Dermira has found favor with the FDA Fast-Track Orphan Drug Status. 

What are the current Stock Analysts giving as their price targets? Seeing the target range is currently between $15 - $22 dollars a share of upside potential, with the most recent news of DERM baked in the FDA recent thumbs-up approval. 

(Click on image to enlarge)

I tend to always use my Fidelity Trading Platform, their P&F charting systems. The chart appearing to the right is one such great example of knowing if the Big Institutions are with me or against me. 

Why did Demira gain this potential to now become a potential M&A candidate or a company with much higher per-share stock prices over the next several years? It goes right back into gaining the coveted FDA approved Orphan Status. What brought this stock issue into my radar as it's high Call options volumes. The Put to Call ratio left the Put(s) severally outnumbered. We see DERM as a potential Price Target given by Louise Chen of Cantor Fitzgerald of $25 dollars a share with all Analysts giving a Buy rating with a few stating a Hold.  Is this stock issue belong in your portfolio? It has found a place currently within mine starting right at the start of December 2019. 

I hope this helps those trying to get a handle on what December can bring as the end of year Christmas gifts.